From: RECK is not an independent prognostic marker for breast cancer
Parameter | RECK negative no. cases (%) | RECK positive no. cases (%) | χ2 | p-value |
---|---|---|---|---|
Age | ||||
  < 50 years | 195 (18.8 %) | 191 (18.4 %) | 0.021 | 0.8848 |
  ≥ 50 years | 324 (31.3 %) | 326 (31.5 %) | ||
Menopausal status | ||||
 Premenopausal | 206 (20.1 %) | 197 (19.1 %) | 0.082 | 0.7752 |
 Postmenopausal | 312 (30.4 %) | 312 (30.4 %) | ||
Tumor size | ||||
  < 5 cm | 252 (25.5 %) | 268 (27.1 %) | 1.494 | 0.2216 |
  ≥ 5 cm | 247 (24.9 %) | 223 (22.5 %) | ||
Lymph node stage | ||||
 Negative (N0) | 169 (16.6 %) | 160 (15.7 %) | 0.243 | 0.6222 |
 Positive (N1, N2, N3) | 341 (33.5 %) | 348 (34.2 %) | ||
Recurrence | ||||
 Negative | 257 (25.1 %) | 259 (25.3 %) | 0.063 | 0.8014 |
 Positive | 258 (25.2 %) | 250 (24.4 %) | ||
ER/PR status | ||||
 ER+/PR+ | 208 (22.3 %) | 204 (22.0 %) | 8.001 | 0.046 |
 ER+/PR- | 125 (13.5 %) | 86 (9.3 %) | ||
 ER-/PR+ | 8 (0.9 %) | 11 (1.2 %) | ||
 ER-/PR- | 135 (14.5 %) | 151 (16.3 %) | ||
Histological grade | ||||
 1 | 86 (8.3 %) | 73 (7.1 %) | 14.257 | 0.0008 |
 2 | 315 (30.5 %) | 273 (26.4 %) | ||
 3 | 116 (11.2 %) | 170 (16.5 %) | ||
TNM stage | ||||
 1 | 39 (3.8 %) | 17 (1.6 %) | 11.069 | 0.0114 |
 2A and 2B | 201 (19.5 %) | 204 (19.7 %) | ||
 3A, 3B, and 3C | 240 (23.2 %) | 240 (23.2 %) | ||
 4 | 39 (3.8 %) | 54 (5.2 %) |